

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

Applicants: David A. Cheresch et al.)

SEP 22 2003

Application No. 09/701,500)

Filed: November 29, 2000)

For: METHODS AND COMPOSITIONS)
USEFUL FOR MODULATION OF)
ANGIOGENESIS USING TYROSINE)
KINASE SRC)

Group Art Unit: 1635

OFFICIAL

Examiner: Richard A. Schnizer)

Attorney Docket No. TSRI 651.1RESPONSE TO RESTRICTION REQUIREMENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated 18 August 2003 on the above-identified application, applicants hereby provisionally elect for prosecution at this time the claims of Group III, i.e., claims 1-4, 12-16, 33 and 34 drawn to compositions comprising a nucleotide sequence capable of expressing an active Src protein. This election is made without traverse.

An early action on the merits is solicited.

Respectfully submitted,

September 18, 2003

By

Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive, 36th Floor
Chicago, Illinois 60606
(312) 580-1180CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being transmitted by facsimile transmission to Examiner Richard Schnizer via Fax No. 703-872-9306 on September 18, 2003.

Talivaldis Cepuritis (Reg. No. 20,818)